{"id":71796,"date":"2013-02-05T15:50:59","date_gmt":"2013-02-05T15:50:59","guid":{"rendered":"http:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/uncategorized\/compugen-to-present-at-the-molecular-medicine-tri-conference-2013-in-san-francisco.php"},"modified":"2013-02-05T15:50:59","modified_gmt":"2013-02-05T15:50:59","slug":"compugen-to-present-at-the-molecular-medicine-tri-conference-2013-in-san-francisco","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/medicine\/compugen-to-present-at-the-molecular-medicine-tri-conference-2013-in-san-francisco.php","title":{"rendered":"Compugen to Present at the Molecular Medicine Tri-Conference\u00a02013 in San Francisco"},"content":{"rendered":"<p><p>      TEL AVIV, Israel--(BUSINESS WIRE)--    <\/p>\n<p>      Compugen Ltd. (CGEN)      today announced that the Company was invited to present at      the       Molecular Medicine Tri-Conference 2013, at Moscone      Convention Center in San Francisco, California.    <\/p>\n<p>      Dr. John Hunter, Vice President, Antibody Research &      Development at Compugen, Inc., a wholly owned subsidiary of      Compugen Ltd., will participate in a session entitled      Cancer Biologics: Approaches Changing the Treatment of      Cancer. Dr. Hunter's presentation entitled       Predictive Drug Discovery for Novel Cancer      Biologics will take place on Thursday, February 14 at      1:45 pm PST. In his talk, Dr. Hunter will demonstrate how      Compugen has applied its predictive discovery platforms to      identify novel immune checkpoints for targeted antibody      immunotherapy in cancer. Validation data for representative      targets will also be presented.    <\/p>\n<p>      About Compugen    <\/p>\n<p>      Compugen is a leading therapeutic product discovery company      focused on therapeutic proteins and monoclonal antibodies to      address important unmet needs in the fields of immunology and      oncology. The Company utilizes a broad and continuously      growing integrated infrastructure of proprietary scientific      understandings and predictive platforms, algorithms, machine      learning systems and other computational biology capabilities      for thein silico(by computer) prediction      and selection of product candidates, which are then advanced      in its Pipeline Program. The Company's business model      includes collaborations covering the further development and      commercialization of selected product candidates from its      Pipeline Program and various forms of research and discovery      agreements, in both cases providing Compugen with potential      milestone payments and royalties on product sales or other      forms of revenue sharing. In 2012, Compugen established      operations in California for the development of oncology and      immunology monoclonal antibody therapeutic candidates against      Compugen drug targets. For additional information, please      visit Compugen's corporate website at       <a href=\"http:\/\/www.cgen.com\" rel=\"nofollow\">http:\/\/www.cgen.com<\/a>.    <\/p>\n<\/p>\n<p><!-- Auto Generated --><\/p>\n<p>Go here to see the original:<\/p>\n<p><a target=\"_blank\" href=\"http:\/\/finance.yahoo.com\/news\/compugen-present-molecular-medicine-tri-120000627.html;_ylt=A2KJNTtIKhFRPj8A2kj_wgt.\" title=\"Compugen to Present at the Molecular Medicine Tri-Conference\u00a02013 in San Francisco\">Compugen to Present at the Molecular Medicine Tri-Conference\u00a02013 in San Francisco<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> TEL AVIV, Israel--(BUSINESS WIRE)-- Compugen Ltd. (CGEN) today announced that the Company was invited to present at the Molecular Medicine Tri-Conference 2013, at Moscone Convention Center in San Francisco, California. Dr <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/medicine\/compugen-to-present-at-the-molecular-medicine-tri-conference-2013-in-san-francisco.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[35],"tags":[],"class_list":["post-71796","post","type-post","status-publish","format-standard","hentry","category-medicine"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/71796"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=71796"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/71796\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=71796"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=71796"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=71796"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}